Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02846935
Recruitment Status : Completed
First Posted : July 27, 2016
Last Update Posted : January 7, 2019
Information provided by (Responsible Party):
Yogen Saunthararajah, Case Comprehensive Cancer Center

Brief Summary:
The purpose of this study is to evaluate how well the study drug works and safety of oral decitabine in patients with refractory or relapsed lymphoid malignancies. The decitabine is being given at a lower dose than used for its approved use. It is also being given with another drug, tetrahydrouridine (THU), to improve the exposure of lymphoma cells to decitabine.

Condition or disease Intervention/treatment Phase
T-cell Lymphoma Aggressive B-cell Lymphoma Non-Hodgkin's Lymphomas Indolent B-cell Lymphoma Drug: Decitabine Drug: Tetrahydrouridine Early Phase 1

Detailed Description:

Primary objective: To determine the objective response rate to oral THU-Dec in patients with 3 separate biologic subsets of refractory/relapsed lymphoid malignancies:

  1. T-cell lymphoma,
  2. Aggressive B cell lymphoma,
  3. indolent B-cell lymphoma .

Secondary objectives:

(i) To evaluate the toxicity of oral THU-Dec in these patients; (ii) To evaluate hypotheses regarding mechanisms of resistance and predictive biomarkers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Actual Study Start Date : April 25, 2017
Actual Primary Completion Date : January 22, 2018
Actual Study Completion Date : January 22, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Decitabine

Arm Intervention/treatment
Experimental: Decitabine + Tetrahydrouridine

oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.

Treatment on protocol monitoring continues for 52 weeks.

Drug: Decitabine
2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
Other Name: DEC

Drug: Tetrahydrouridine
2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
Other Name: THU

Primary Outcome Measures :
  1. Objective Response by Revised Response Criteria for Malignant Lymphoma [ Time Frame: Up to 52 weeks ]

Secondary Outcome Measures :
  1. Complete Response [ Time Frame: Up to 52 weeks ]
    Complete disappearance of all detectable clinical evidence of disease, and disease-related symptoms if present prior to therapy

  2. Partial Response [ Time Frame: Up to 52 weeks ]

    A > 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or extranodal masses. These nodes should be selected according to the following: (a) they should be clearly measurable in at least 2 perpendicular dimensions; (b) they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.

    No increase in the size of other nodes, liver or spleen.

    Bone marrow assessment is irrelevant for determination of a PR if the sample was positive prior to treatment. However, if positive, the cell type should be specified, e.g. large-cell lymphoma or small cleaved cell lymphoma.

    No new sites of disease

  3. Stable Disease [ Time Frame: Up to 52 weeks ]

    Failing to attain the criteria needed for a PR or CR, but not fulfilling those for progressive disease.

    For FDG-avid lymphomas: FDG-PET/CT should be positive at prior sites of disease with no new areas of involvement on the post-treatment CT or FDG-PET/CT.

    For variably FDG-avid lymphomas/FDG-avidity unknown: For patients without a pretreatment FDG-PET/CT scan or if the pre-treatment FDG-PET/CT was negative, there must be no change in the size of the previous lesions on the post-treatment CT scan.

  4. Progressive Disease [ Time Frame: Up to 52 weeks ]
    For determination of relapsed and progressive disease, lymph nodes should be considered abnormal if the long axis is more than 1.5 cm, regardless of the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be considered abnormal if the short axis is more than 1 cm. Lymph nodes < 1 x < 1 cm will not be considered as abnormal for relapse or progressive disease. Treatment decisions in patients with presumed refractory, relapsed or progressive disease should not be made solely on the basis of a single FDG-PET/CT scan without histologic confirmation.

  5. Duration of response [ Time Frame: Up to 52 weeks ]
    This is measured, only in responders, from the documented beginning of response (CR or PR) to the time of relapse.

  6. Disease-free survival [ Time Frame: Up to 52 weeks ]
    Survival is defined as the date of study entry to the date of death. Disease-free survival is measured from the time of occurrence of disease-free state (e.g. the adjuvant setting following surgery or radiation therapy) or attainment of a complete remission) to disease recurrence or death from lymphoma or acute toxicity of treatment. This definition may be complicated by deaths that occur during the follow-up period that are unrelated to the lymphoma and there is controversy as to whether such deaths should be considered as events or censored at the time of occurrence. Whereas it is often possible to identify those deaths related to the lymphoma, there is the potential for bias in the attribution of deaths.

  7. Disease-specific survival [ Time Frame: Up to 52 weeks ]
    Disease-specific survival (e.g., lymphoma-specific survival, cause-specific survival) is potentially subject to bias because the exact cause of death is not always easy to ascertain. To minimize the risk of bias, the event should be recorded as death from lymphoma, or from toxicity from the drug. Death from unknown causes should be attributed to the drug. For certain trials, time to next lymphoma treatment may be of interest, defined as time from the end of primary treatment until the initiation of the next therapy.

  8. Progression-free survival [ Time Frame: Up to 52 weeks ]
    Progression-free Survival (PFS) is defined as the time from entry onto study until lymphoma progression or death from any cause. PFS reflects tumor growth and, therefore, occurs prior to the endpoint of overall survival. In addition, PFS is not confounded by the administration of subsequent therapy. Whether a prolongation of PFS represents direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the risk-benefit ratio of the therapy under investigation. Unlike survival, the precise date of progression is generally unknown. It may be defined as the first date of documentation of a new lesion or enlargement of a previous lesion, or the date of the scheduled clinic visit immediately after radiologic assessment has been completed. Where there is missing information, censoring of the data may be defined as the last date at which progression status was adequately assessed or the first date of unscheduled new anti-lymphoma treatment.

  9. Time to progression [ Time Frame: Up to 52 weeks ]
    Time to progression (TTP) is defined as the time from study entry until lymphoma progression or death due to lymphoma. In TTP, deaths from other causes are censored either at the time of death or at an earlier time of assessment, representing a random pattern of loss from the study. TTP is not as useful as PFS unless the majority of deaths on a study are unrelated to the lymphoma due to the efficacy of the treatment and/or prolonged follow up

  10. Time to treatment failure [ Time Frame: Up to 52 weeks ]
    Time to treatment failure (event-free survival) is measured from the time from study entry to any treatment failure including discontinuation of treatment for any reason, such as disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death. This composite endpoint is generally not encouraged by regulatory agencies because it combines efficacy, toxicity and patient withdrawal.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically-proven T- or B-cell lymphoma
  • Subjects must have received 1 or more prior therapies for this disease and have had stable disease or progressive disease based upon the criteria from the Revised Response Criteria for Malignant Lymphoma78, or intolerable toxicities precluding further therapy with a prior regimen
  • Subjects must have measurable disease per Revised Response Criteria for Malignant Lymphoma78
  • ECOG performance status 0 - 2
  • Adequate organ function as defined by the following criteria:

    • Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x laboratory upper limit of normal (ULN)
    • Total serum bilirubin ≤ 2.0 x ULN (except if Gilbert's disease)
    • Absolute neutrophil count (ANC) ≥ 1500/uL
    • Platelets ≥ 50,000/uL
    • Hemoglobin ≥ 8.0 g/dL (transfusion permitted)
    • Serum calcium ≤ 12.0 mg/dL
    • Serum Creatinine ≤ 3.0 mg/dL
  • Patients with history of CNS lymphoma can be enrolled if the CNS disease has been controlled with therapy for a minimum of 4 weeks. Brain MRI is not required for eligibility.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Life expectancy ≤ 4 months in the judgment of the treating clinician
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with oral THU-Dec. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated.
  • Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study because oral THU-Dec has the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential, risk for adverse events in nursing infants secondary to treatment of the mother with oral THU-Dec, breastfeeding should be discontinued if the mother is treated with oral THU-Dec.
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
  • Receiving other investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02846935

Layout table for location information
United States, Ohio
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Yogen Saunthararajah
Layout table for investigator information
Principal Investigator: Brian Hill, MD, PhD Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Yogen Saunthararajah, Professor of Hematology and Oncology, Case Comprehensive Cancer Center Identifier: NCT02846935    
Other Study ID Numbers: CASE1416
First Posted: July 27, 2016    Key Record Dates
Last Update Posted: January 7, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yogen Saunthararajah, Case Comprehensive Cancer Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors